Metagenomi, Inc.
MGX
$1.56
-$0.05-2.81%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 8.66M | 8.51M | 4.13M | 9.61M | 11.51M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.66M | 8.51M | 4.13M | 9.61M | 11.51M |
| Cost of Revenue | 25.28M | 22.51M | 25.14M | 23.16M | 26.26M |
| Gross Profit | -16.62M | -13.99M | -21.02M | -13.55M | -14.74M |
| SG&A Expenses | 6.22M | 6.99M | 6.81M | 7.07M | 7.64M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.50M | 29.50M | 31.95M | 30.24M | 33.90M |
| Operating Income | -22.84M | -20.99M | -27.82M | -20.62M | -22.38M |
| Income Before Tax | -20.63M | -19.86M | -24.94M | -24.61M | -20.88M |
| Income Tax Expenses | -234.00K | 44.00K | 98.00K | -1.21M | -2.11M |
| Earnings from Continuing Operations | -20.39M | -19.91M | -25.04M | -23.40M | -18.77M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.39M | -19.91M | -25.04M | -23.40M | -18.77M |
| EBIT | -22.84M | -20.99M | -27.82M | -20.62M | -22.38M |
| EBITDA | -21.52M | -19.65M | -26.46M | -19.16M | -21.02M |
| EPS Basic | -0.55 | -0.54 | -0.68 | -0.63 | -0.51 |
| Normalized Basic EPS | -0.35 | -0.31 | -0.42 | -0.29 | -0.32 |
| EPS Diluted | -0.55 | -0.54 | -0.68 | -0.63 | -0.51 |
| Normalized Diluted EPS | -0.35 | -0.31 | -0.42 | -0.29 | -0.32 |
| Average Basic Shares Outstanding | 37.35M | 37.16M | 37.02M | 37.31M | 36.77M |
| Average Diluted Shares Outstanding | 37.35M | 37.16M | 37.02M | 37.31M | 36.77M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |